FDA Proposes Excluding Novo, Lilly Weight Loss Drugs from Bulk Compounding List

The FDA has proposed excluding weight loss drugs from Novo and Lilly from the bulk compounding list, a move that would benefit the pharmaceutical companies.

30 Apr, 15:02 — 30 Apr, 15:02

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual123d ago

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's ⁠drug shortage ⁠list.

Read full article →

FDA Proposes Excluding Novo, Lilly Weight Loss Drugs from Bulk Compounding List

Sources

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

Related Stories

Shein Shares Drop 10 Percent in Hong Kong Stock Exchange Debut

South Korea Reports Record Export Surge in August Driven by Semiconductor Demand

South Korean and Turkish Defense Firms Climb Global Industry Rankings

OpenAI and Apple Trade Accusations in Ongoing Trade Secrets Litigation